Why participate?
Present the key challenges in viral vector production and provide the foundational knowledge needed to guide strategic choices in vector development
Training Context:
Viral vectors are a fundamental technological component in gene therapy strategies, whether in vivo or ex vivo. The Advanced Therapy Medicinal Products (ATMP) market is rapidly expanding, and viral vectors—used both as therapeutic agents and as technological tools (e.g., in CAR T-cell development)—are becoming increasingly important products of choice.
Interactive Teaching, Case Studies, Experience Sharing
All scientific audiences: R&D managers, project leaders, academic researchers, engineers, technicians
Fundamental knowledge of biotechnology or molecular biology required
Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.
Registering online or by e-mail is a pre-registration. We will process your request within one week:
Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.
When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.
For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr
